Low pyridoxine levels and its association with the onset of gastrointestinal intolerance to oral levodopa in patients with Parkinson's disease: a cohort study
Text Complet
Compartir
BACKGROUND
Parkinson's disease (PD) is the second most common neurodegenerative disease
consisting of the presence of motor symptoms, bradykinesia plus stiffness, tremor or
instability and other non-motor symptoms. PD has a high prevalence. The etiology of
the disease is unknown in most cases although risk factors related to its occurrence
have been identified. Its diagnosis is based on the clinic. There is no curative treatment
but symptomatic treatments. Several pharmacological groups can be considered in
patients with PD, but still after 50 years of its onset the choice for most patients is L-
DOPA, the most effective drug to treat the symptoms of the disease. The progression
of the disease over time implies the need to increase doses of this drug or changes in
the form of administration. A high percentage of patients taking this drug have adverse
reactions, most of them motor but a considerable percentage also present adverse
digestive reactions. In the metabolic pathway of this drug participate some B- complex
vitamins such as pyridoxine, cobalamin, folic acid, and other biomolecules such as
homocysteine.
OBJECTIVE
The aim of this study is to assess whether low pyridoxine levels influence the onset of
gastrointestinal intolerance to L-DOPA in patients with Parkinson’s disease.
DESIGN
The study is designed as a multicenter observational prospective cohort study in
reference hospitals of Catalonia.
PARTICIPANTS
All patients with Parkinson's disease who start oral L-DOPA treatment (n=280) and
meet the selection criteria will participate in this study.
METHODS
Pyridoxine and covariate values (B12, folic acid and homocysteine) will be obtained
from blood tests. To assess gastrointestinal intolerance patients will respond a survey
of gastrointestinal tolerance to L-DOPA within three months of starting treatment.
Subsequently we will carry out a statistical analysis to compare which percentage of
cases appears in relation to low levels of pyridoxine compared to the group that does
not have them low